Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
Launched by LUNG CANCER GROUP COLOGNE · Dec 5, 2007
Trial Information
Current as of June 22, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent
- • ≥ 18 years of age
- • Untreated non-small-cell lung cancer stage IIIB/IV
- • Life expectancy \> 3 months
- • Performance status ECOG 0-2
- Exclusion Criteria:
- • Concurrent systemic immune therapy, chemotherapy or therapy with any anticancer drug not indicated in the study protocol
- • Any investigational agent(s) within 4 weeks prior to study entry
- • Previous administration of any EGFR-targeted therapy (antibodies, small molecules and others)
- • Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
About Lung Cancer Group Cologne
The Lung Cancer Group Cologne is a dedicated clinical research organization focused on advancing the understanding, diagnosis, and treatment of lung cancer. Comprising a multidisciplinary team of oncologists, researchers, and healthcare professionals, the group conducts innovative clinical trials aimed at developing novel therapeutic strategies and improving patient outcomes. With a commitment to collaboration and excellence, the Lung Cancer Group Cologne actively engages in partnerships with academic institutions and industry stakeholders, fostering an environment of rigorous scientific inquiry and patient-centered care in the fight against lung cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cologne, , Germany
Patients applied
Trial Officials
Juergen Wolf, Prof., Dr.
Principal Investigator
University Cologne, Lung Cancer Group Cologne
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials